Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
SRTX has been attempting to raise fresh financing needed to fund its near-term working capital requirements and stretch its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback